Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs

被引:2
作者
Liang, Shuang [1 ]
Wang, Xianying [1 ]
Zhu, Xiuqing [2 ,3 ]
机构
[1] Hebei Med Univ, Hosp 3, Dept Pharm, Shijiazhuang, Peoples R China
[2] Guangzhou Med Univ, Key Lab Neurogenet & Channelopathies, Guangdong Prov & Minist Educ China, Guangzhou, Peoples R China
[3] Guangzhou Med Univ, Affiliated Brain Hosp, Dept Pharm, Guangzhou, Peoples R China
关键词
NSAIDs; cardiovascular safety signals; FAERS; OpenVigil; 2.1; pharmacovigilance; pharmacodynamics; cyclooxygenase-1; cyclooxygenase-2; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COX-2; INHIBITORS; DISEASE; RISK;
D O I
10.3389/fphar.2024.1455212
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Aim Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat fever, pain, and inflammation. Concerns regarding their cardiovascular safety have been raised. However, the underlying mechanism behind these events remains unknown. We aim to investigate the cardiovascular safety signals and receptor mechanisms of NSAIDs, employing a comprehensive approach that integrates pharmacovigilance and pharmacodynamics.Methods This study utilized a pharmacovigilance-pharmacodynamic approach to evaluate the cardiovascular safety of NSAIDs and explore potential receptor mechanisms involved. Data were analyzed using the OpenVigil 2.1 web application, which grants access to the FDA Adverse Event Reporting System (FAERS) database, in conjunction with the BindingDB database, which provides target information on the pharmacodynamic properties of NSAIDs. Disproportionality analysis employing the Empirical Bayes Geometric Mean (EBGM) and Reporting Odds Ratio (ROR) methods was conducted to identify signals for reporting cardiovascular-related adverse drug events (ADEs) associated with 13 NSAIDs. This analysis encompassed three System Organ Classes (SOCs) associated with the cardiovascular system: blood and lymphatic system disorders, cardiac disorders, and vascular disorders. The primary targets were identified through the receptor-NSAID interaction network. Ordinary least squares (OLS) regression models explored the relationship between pharmacovigilance signals and receptor occupancy rate.Results A total of 201,231 reports of cardiovascular-related ADEs were identified among the 13 NSAIDs. Dizziness, anemia, and hypertension were the most frequently reported Preferred Terms (PTs). Overall, nimesulide and parecoxib exhibited the strongest signal strengths of ADEs at SOC levels related to the cardiovascular system. On the other hand, our data presented naproxen and diclofenac as drugs of comparatively low signal strength. Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) were identified as central targets. OLS regression analysis revealed that the normalized occupancy rate for either COX-1 or COX-2 was significantly inversely correlated with the log-transformed signal measures for blood and lymphatic system disorders and vascular disorders, and positively correlated with cardiac disorders and vascular disorders, respectively. This suggests that higher COX-2 receptor occupancy is associated with an increased cardiovascular risk from NSAIDs.Conclusion Cardiovascular safety of NSAIDs may depend on pharmacodynamic properties, specifically, the percentage of the occupied cyclooxygenase isoenzymes. More studies are needed to explore these relations and improve the prescription process.
引用
收藏
页数:14
相关论文
共 50 条
[21]   Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis [J].
Park, Taehwan ;
Hwang, Monica .
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2024, 22 (06) :273-283
[22]   The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy [J].
Sportiello, Liberata ;
Rafaniello, Concetta ;
Scavone, Cristina ;
Vitale, Cristiana ;
Rossi, Francesco ;
Capuano, Annalisa .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 202 :731-735
[23]   Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024 [J].
Zheng, Fuchun ;
Yang, Xin ;
Li, Sheng ;
Yuan, Yuyang ;
Wang, Zhipeng ;
Xiong, Situ ;
Fu, Bin ;
Liu, Wei ;
Lu, Qi .
EXPERT OPINION ON DRUG SAFETY, 2025, 24 (05) :557-564
[24]   Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS [J].
Zhou, Xiang ;
Ye, Xiaofei ;
Guo, Xiaojing ;
Liu, Dongxu ;
Xu, Jinfang ;
Hu, Fangyuan ;
Zhai, Yinghong ;
Gao, Yongqing ;
Xu, Xiao ;
Dong, Ziwei ;
He, Jia .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[25]   New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017 [J].
Farcas, Andrea ;
Mahalean, Andreea ;
Bulik, Noemi Beatrix ;
Leucuta, Daniel ;
Mogosan, Cristina .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (10) :1045-1051
[26]   What Affects the Quality of Pharmacovigilance? Insights From Qualitative Comparative Analysis [J].
Wang, Yadong ;
Chen, Yue ;
Xu, Xingjuan ;
Ying, Ting ;
Xia, Runan ;
Zhang, Yuanyuan ;
Xie, Xuefeng .
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2025, 13 (03)
[27]   Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology [J].
Xie, Hao ;
Xu, Qiang ;
Zhao, Bin ;
Wu, Wenming .
EXPERT OPINION ON DRUG SAFETY, 2025,
[28]   Post-market safety profile and suicide/self-injury risk signals of dextromethorphan/bupropion: a real-world pharmacovigilance study [J].
Yuan, Lingjing ;
He, Jianping ;
Li, Xiangyu .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (07) :1029-1041
[29]   Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran) [J].
Valnet-Rabier, Marie -Blanche ;
Tebacher, Martine ;
Gautier, Sophie ;
Micallef, Joelle ;
Salvo, Francesco ;
Pariente, Antoine ;
Bagheri, Haleh .
THERAPIE, 2023, 78 (05) :499-507
[30]   Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database [J].
Wang, Junwei ;
Zhang, Aiwei ;
Ye, Miaoyong ;
Zhang, Cunming .
FRONTIERS IN PHARMACOLOGY, 2024, 15